HSIC vs MCK: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of August 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. HSIC and MCK share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined HSIC and MCK exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Henry Schein sells the products a dental office or a physician's practice consumes every day: consumables, small equipment, implants, orthodontic aligners, endodontic and biomaterial products, plus the software that runs the front desk and the billing. It reports in three pieces. Global Distribution and Value-Added Services is the large, low-margin core that moves other manufacturers' goods to roughly a million customers across dozens of countries. Global Specialty Products covers the higher-margin implant, orthodontic and biomaterials lines the company mostly bought. Global Technology sells practice-management and revenue-cycle software, including the Dentrix family, and carries by far the best economics in the company (segment operating margin of roughly 27% in Q2 2026 on segment operating income of about $49 million). Specialty and technology together contribute around half of operating income on a small fraction of revenue, which is the whole strategic point.

Full HSIC guide

McKesson Corporation is a healthcare-services and pharmaceutical-distribution company, one of the "Big Three" US drug wholesalers alongside Cencora (formerly AmerisourceBergen) and Cardinal Health that together handle the large majority of prescription drugs sold in the country. In fiscal 2026 the company reported roughly $337 billion in revenue, the bulk of it from its North American Pharmaceutical segment, which sources, warehouses, and delivers branded, generic, and specialty medicines to pharmacies, health systems, and providers. Because distribution is a scale game with very low margins, McKesson competes on logistics efficiency, breadth of contracts, and reliability rather than pricing power on the drugs themselves.

Full MCK guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• HSIC drivers: Mix shift toward specialty and technology; The value-creation and restructuring program.
• MCK drivers: Defensive, volume-driven distribution core; Specialty and oncology services mix-shift.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: Distribution economics are thin, so a small swing in product mix or in supplier rebates moves earnings more than revenue growth suggests. For MCK, the central structural risk is razor-thin distribution margins: on hundreds of billions of revenue McKesson keeps only a small fraction as profit, so even modest cost inflation, contract losses, or generic-pricing deflation can pressure results.

Pick HSIC if you believe its drivers more; MCK if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the HSIC and MCK guides.

HSIC. At roughly $89.77 against guided non-GAAP EPS of about $5.29 to $5.39, HSIC trades near 17 times this year's adjusted earnings, and under 0.8 times sales. The sales multiple is the one that matters least here, since distribution revenue converts to profit at a very low rate, and the adjusted multiple is the one that carries the most assumption risk, since restructuring charges running through 2027 keep GAAP results well below it. The gap between the two is effectively the market's discount on whether the margin program sticks.

MCK. All figures are approximate, tied to the asOf date, and blend fiscal-year and quarterly disclosures; verify live numbers before acting. Note McKesson reports on a fiscal year ending in March, so "fiscal 2026" spans calendar 2025 into early 2026. Because distribution revenue is enormous but low-margin, revenue-based multiples are misleading here: analysts focus on adjusted EPS growth, free cash flow, and the mix-shift toward higher-margin services.

Headline figures (approximate, August 2026): HSIC shows revenue (ttm) ~$13.60B, market cap ~$10.2B, share price ~$89.77, q2 2026 sales ~$3.5B, up ~6.7% year over year; MCK shows revenue (fy2026) ~$337 billion, the vast majority from North American pharmaceutical distribution (approximate; verify live), segment profit mix North American Pharmaceutical ~$3.5B adjusted operating profit; Oncology & Multispecialty ~$1.4B; Prescription Technology ~$1.1B (approximate), margin profile Very low overall (low-single-digit operating margin) because distribution dominates revenue; services segments carry much higher margins, earnings trend Management raised full-year adjusted EPS guidance multiple times through fiscal 2026 (qualitative; confirm latest figures).

HSIC and MCK are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined HSIC and MCK exposure against your real portfolio. It is not an investment adviser.